Skip to main content

Bright Minds Biosciences Inc. (NASDAQ: DRUG) Leading the Way in Tuesday Trading Based on Percentage Gain

Bright Minds Biosciences Inc. (NASDAQ: DRUG) is one of today’s top gainers. The company’s shares are currently up 46.58% on the day to $4.72.

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy and University of Texas Medical Branch to treat impulse control disorders.

So far today, approximately 26.66M shares of Bright Minds Biosciences Inc. have been exchanged, as compared to an average 30-day volume of 120.38k shares.

Bright Minds Biosciences Inc. share prices have moved between a 52-week high of $23.75 and a 52-week low of $2.01. The stock has moved 4.43% over the past week.

To learn more about Bright Minds Biosciences Inc., visit the company’s website at

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Los Angeles, California
310.299.1717 Office

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.